Core Insights - NWPX Infrastructure reported revenue of $133.18 million for Q2 2025, a year-over-year increase of 2.8% and exceeding the Zacks Consensus Estimate of $120.39 million by 10.63% [1] - The company achieved an EPS of $0.91, up from $0.86 a year ago, representing a surprise of 26.39% compared to the consensus estimate of $0.72 [1] Financial Performance Metrics - Net Sales for Precast Infrastructure and Engineered Systems reached $48.59 million, surpassing the average estimate of $41.96 million, with a year-over-year increase of 21.5% [4] - Net Sales for Water Transmission Systems were reported at $84.59 million, exceeding the average estimate of $78.43 million, but reflecting a year-over-year decline of 5.5% [4] - Gross profit for Precast Infrastructure and Engineered Systems was $10.31 million, above the average estimate of $9.92 million [4] - Gross profit for Water Transmission Systems was $15.06 million, compared to the average estimate of $12.82 million [4] Stock Performance - NWPX Infrastructure shares have returned -0.5% over the past month, while the Zacks S&P 500 composite has increased by 1.2% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating potential performance in line with the broader market in the near term [3]

Core Insights - Akamai Technologies reported revenue of $1.04 billion for the quarter ended June 2025, reflecting a year-over-year increase of 6.5% [1] - Earnings per share (EPS) for the quarter was $1.73, up from $1.58 in the same quarter last year, representing an EPS surprise of +11.61% against the consensus estimate of $1.55 [1] - The reported revenue exceeded the Zacks Consensus Estimate of $1.02 billion by +2.17% [1] Revenue Breakdown - Security revenue was $551.91 million, slightly below the average estimate of $553.57 million, with a year-over-year increase of +10.7% [4] - Compute revenue reached $171.46 million, compared to the average estimate of $173.75 million, marking a year-over-year increase of +13.2% [4] - Delivery revenue was reported at $320.13 million, exceeding the estimated $295.2 million, but showing a year-over-year decline of -2.8% [4] Stock Performance - Over the past month, shares of Akamai Technologies have returned -7.6%, contrasting with the Zacks S&P 500 composite's +1.2% change [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

In its upcoming report, Telephone & Data Systems (TDS) is predicted by Wall Street analysts to post quarterly loss of -$0.01 per share, reflecting an increase of 92.3% compared to the same period last year. Revenues are forecasted to be $1.17 billion, representing a year-over-year decrease of 5.7%. The current level reflects no revision in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projec ...

Core Viewpoint - Carlyle Group (CG) is expected to report quarterly earnings of $0.91 per share, reflecting a 16.7% increase year-over-year, with revenues projected at $957.66 million, a 21.4% increase compared to the previous year [1]. Earnings Estimates - Over the last 30 days, the consensus EPS estimate has been revised downward by 0.6%, indicating a collective reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate revisions and short-term stock performance [3]. Revenue Projections - Analysts predict 'Segment Revenues- Realized principal investment income (loss)' at $28.84 million, an increase of 8.4% year-over-year [5]. - 'Segment Revenues- Realized performance revenues' is expected to reach $287.63 million, suggesting an 83.8% increase compared to the prior year [5]. - 'Segment Revenues- Fund management fees' is forecasted at $549.04 million, indicating a 4.5% year-over-year change [6]. - 'Segment Revenues- Transaction and portfolio advisory fees, net and other' is estimated to be $35.26 million, reflecting a 22% increase from the previous year [6]. Assets Under Management (AUM) Projections - 'Total AUM Roll Forward - Global Private Equity - EOP' is projected to be $163.92 billion, slightly down from $164.23 billion year-over-year [7]. - 'Total AUM Roll Forward - Global Investment Solutions - EOP' is expected to reach $88.23 billion, up from $80.63 billion in the same quarter last year [7]. - 'Total AUM Roll Forward - EOP' is anticipated to be $456.52 billion, compared to $434.62 billion reported in the same quarter last year [8]. - 'Fee-earning AUM Roll Forward - Global Private Equity - EOP' is projected at $103.54 billion, slightly down from $103.66 billion year-over-year [8]. - 'Fee-earning AUM Roll Forward - Global Credit - EOP' is expected to reach $164.74 billion, up from $155.44 billion in the same quarter last year [9]. - 'Total AUM Roll Forward - Global Credit - EOP' is projected at $204.37 billion, compared to $189.76 billion year-over-year [9]. - 'Fee-earning AUM Roll Forward - Global Investment Solutions - EOP' is estimated at $55.70 billion, up from $48.25 billion in the same quarter last year [10]. - 'Total Fee-earning AUM Roll Forward - EOP' is expected to be $323.98 billion, compared to $307.35 billion reported in the same quarter last year [10]. Stock Performance - Over the past month, Carlyle shares have increased by 9.9%, outperforming the Zacks S&P 500 composite, which saw a 1% change [11].

Core Insights - Corpay (CPAY) is expected to report quarterly earnings of $5.13 per share, reflecting a year-over-year increase of 12.8% [1] - Anticipated revenues for the quarter are projected to be $1.1 billion, which represents a 12.7% increase compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has been revised 1.2% higher over the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3] Revenue Forecasts - Analysts predict 'Revenues- Corporate Payments' will reach $385.68 million, a year-over-year increase of 33.7% [5] - 'Revenues- Vehicle Payments' are expected to be $525.69 million, showing a 3% increase year-over-year [5] - 'Revenues- Lodging Payments' are forecasted at $122.91 million, indicating a slight increase of 0.4% from the previous year [5] - 'Revenues- Other Payments' are estimated to be $61.97 million, reflecting a 13.5% increase from the prior year [6] Transaction and Operating Income Estimates - 'Spend volume - Corporate Payments' is projected to reach 54.03 million, up from 42.88 million in the same quarter last year [7] - 'Operating income- Corporate Payments' is expected to be $144.83 million, compared to $120.56 million in the previous year [9] - 'Operating income- Vehicle Payments' is forecasted at $259.50 million, up from $242.03 million year-over-year [9] - 'Operating income- Lodging' is estimated to be $55.18 million, slightly down from $56.39 million in the same quarter last year [10] Market Performance - Corpay shares have decreased by 6.7% in the past month, contrasting with a 0.6% increase in the Zacks S&P 500 composite [10]

Core Viewpoint - Amgen is expected to report quarterly earnings of $5.25 per share, reflecting a 5.6% increase year-over-year, with revenues forecasted at $8.86 billion, also representing a 5.6% year-over-year increase [1]. Earnings Estimates - Over the past 30 days, the consensus EPS estimate has been adjusted downward by 0.2%, indicating a reassessment by analysts [2]. - Changes in earnings estimates are crucial for predicting investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock performance [3]. Revenue and Product Sales Estimates - The consensus estimate for 'Revenue- Product sales' is $8.49 billion, indicating a year-over-year change of +5.6% [5]. - Analysts project 'Product Sales- Neulasta- Total' to reach $92.14 million, reflecting a -12.3% change from the previous year [5]. - 'Product Sales- LUMAKRAS/LUMYKRAS- Total' is expected to be $91.20 million, showing a +7.3% year-over-year change [5]. - 'Product Sales- Otezla- Total' is estimated at $533.54 million, indicating a -1.9% change year-over-year [6]. - 'Product Sales- Neulasta- ROW' is projected at $23.31 million, reflecting a -22.3% change year-over-year [6]. - 'Product Sales- Neulasta- U.S.' is expected to be $66.88 million, indicating a -10.8% change from the prior year [6]. - 'Product Sales- Vectibix- ROW' is estimated at $135.60 million, showing a -1% change from the previous year [7]. - 'Product Sales- Vectibix- U.S.' is forecasted to reach $141.96 million, reflecting a +6.7% year-over-year change [7]. - 'Product Sales- Enbrel- U.S.' is expected to be $786.00 million, indicating a -12.9% change from the prior year [7]. - 'Product Sales- Enbrel- ROW' is projected at $7.01 million, reflecting a +0.1% change year-over-year [8]. - 'Product Sales- Aranesp- ROW' is estimated at $251.00 million, indicating a -2.3% change year-over-year [8]. - 'Product Sales- Aranesp- U.S.' is expected to be $80.25 million, reflecting a -11.8% change from the previous year [8]. Stock Performance - Over the past month, Amgen shares have recorded a return of +1.5%, compared to the Zacks S&P 500 composite's +2.7% change [9].

Core Insights - Imperial Oil (IMO) is expected to report quarterly earnings of $1.22 per share, a decline of 20.8% year-over-year, with revenues projected at $10.54 billion, reflecting a 7.8% increase compared to the previous year [1] Earnings Estimates - The consensus EPS estimate has been revised 1.4% higher over the last 30 days, indicating a collective reevaluation by analysts [2] - Revisions to earnings estimates are crucial indicators for predicting investor actions regarding the stock, with empirical research showing a strong correlation between earnings estimate trends and short-term stock price performance [3] Key Metrics Projections - Analysts estimate 'Gross Oil - Equivalent Production' to reach 416 thousand barrels, up from 404 thousand barrels year-over-year [5] - 'Gross Natural Gas Production' is forecasted at 29.59 thousand cubic feet, slightly down from 30.00 thousand cubic feet in the same quarter last year [5] - 'Gross Total Crude Oil Production' is projected at 410 thousand barrels, compared to 399 thousand barrels in the same quarter of the previous year [6] - 'Net Crude Oil and NGL Production per day - Kearl' is expected to be 173 thousand barrels, up from 167 thousand barrels year-over-year [7] - 'Net Crude Oil and NGL Production per day - Cold Lake' is estimated at 109 thousand barrels, consistent with the previous year's figure [8] - 'Gross Crude Oil and NGL Production per day - Syncrude' is projected at 79 thousand barrels, an increase from 66 thousand barrels year-over-year [9] - 'Total Refinery Throughput' is estimated at 393 thousand barrels, up from 387 thousand barrels in the same quarter last year [10] - 'Net Petroleum Products Sales' is expected to be 458 thousand barrels, down from 470 thousand barrels in the same quarter last year [11] Stock Performance - Over the past month, shares of Imperial Oil have returned +4.1%, outperforming the Zacks S&P 500 composite's +2.7% change [12] - Currently, Imperial Oil holds a Zacks Rank 3 (Hold), suggesting its performance may align with the overall market in the near future [12]

In its upcoming report, Ameren (AEE) is predicted by Wall Street analysts to post quarterly earnings of $1.00 per share, reflecting an increase of 3.1% compared to the same period last year. Revenues are forecasted to be $1.88 billion, representing a year-over-year increase of 10.8%. The consensus EPS estimate for the quarter has undergone an upward revision of 1.2% in the past 30 days, bringing it to its present level. This represents how the covering analysts, as a whole, have reassessed their initial est ...

Wall Street analysts expect PTC Inc. (PTC) to post quarterly earnings of $1.22 per share in its upcoming report, which indicates a year-over-year increase of 24.5%. Revenues are expected to be $582.4 million, up 12.3% from the year-ago quarter. The current level reflects an upward revision of 0.1% in the consensus EPS estimate for the quarter over the past 30 days. This demonstrates how the analysts covering the stock have collectively reappraised their initial projections over this period. Prior to a compa ...

Core Insights - Humana (HUM) is expected to report quarterly earnings of $6.32 per share, reflecting a decline of 9.2% year over year, while revenues are forecasted to reach $31.78 billion, an increase of 8.2% year over year [1] Earnings Estimates - Analysts have revised the consensus EPS estimate down by 0.1% over the past 30 days, indicating a collective reassessment of projections [1][2] Revenue Breakdown - 'Revenues- Premiums' are projected to be $30.23 billion, showing a year-over-year increase of 7.4% [4] - 'Revenues- Services' are estimated at $1.31 billion, indicating a significant year-over-year growth of 19% [4] - 'Revenues- Investment income (loss)' is expected to be $270.96 million, reflecting a decline of 9.1% from the previous year [4] - 'Revenue- Insurance' is anticipated to reach $30.71 billion, marking a 7.7% increase from the prior year [5] Membership Metrics - 'Medical Membership - Medicare stand-alone PDP' is projected to reach 2.45 million, up from 2.34 million in the same quarter last year [6] - 'Medical Membership - State-based contracts and other' is expected to be 1.62 million, compared to 1.39 million a year ago [6] - 'Medical Membership - Group Medicare Advantage' is estimated at 562.63 thousand, an increase from 544.90 thousand year-over-year [7] - 'Medical Membership - Medicare Supplement' is forecasted to reach 419.63 thousand, up from 339.20 thousand in the same quarter last year [7] - 'Medical Membership - Individual Medicare Advantage' is expected to decline to 5.18 million from 5.62 million year-over-year [8] - Total 'Medical Membership - Total Medicare' is projected at 8.19 million, down from 8.50 million a year ago [8] - 'Medical Membership - Military services' is estimated to be 4.94 million, compared to 5.96 million in the previous year [9] Stock Performance - Humana shares have decreased by 1.6% over the past month, contrasting with a 4.9% increase in the Zacks S&P 500 composite [9]